Dividend on the way · $0.72
Labcorp
Provides clinical diagnostics and global laboratory support for biopharma research.
$333.00
After-hours close−2.27 (−0.68%)
At close$335.27(−0.38%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 140.10%Insiders 0.38%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 82.00M · Float 81.67M · 99.6% free float
Institutions13F, as of Jun 30, 2026
1,065 holders · 114.88M shares · 110 new positions · 464 increased · 391 reduced · 88 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 6.57M | 8.02% | +129.4K | Aug 7, 2026 |
| Vanguard Capital Management LLC | 5.36M | 6.54% | −13.9K | Aug 13, 2026 |
| Victory Capital Management Inc | 4.84M | 5.90% | +210.4K | Aug 7, 2026 |
| State Street Corp | 3.91M | 4.77% | +44.5K | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 3.68M | 4.49% | −1.9K | Aug 13, 2026 |
| Boston Partners | 3.05M | 3.72% | +682.9K | Aug 4, 2026 |
| Allspring Global Investments Holdings, LLC | 2.24M | 2.73% | +10.5K | Aug 13, 2026 |
| Geode Capital Management, LLC | 2.19M | 2.67% | +2.9K | Aug 12, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 7.60% | 6.33M | 13G | Apr 24, 2025 ↗ |
| Vanguard Capital Management | 7.52% | 6.20M | 13G | Apr 28, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Adam H. Schechter | director, officer: President & CEO | 102.6K | 0.13% | Aug 12, 2026 |
| Glenn A. Eisenberg | officer: Executive Vice President | 37.9K | 0.05% | Mar 31, 2025 |
| Brian J. Caveney | officer: EVP, Pres of ED, CMO & CSO | 35.4K | 0.04% | Mar 30, 2026 |
| Lance Berberian | officer: EVP, Special Advisor, Strategy | 18.7K | 0.02% | Mar 31, 2025 |
| Peter M. Neupert | director | 13.8K | 0.02% | Feb 13, 2026 |
| Garheng Kong | director | 13.7K | 0.02% | Feb 13, 2026 |
| Mark S. Schroeder | officer: EVP, Pres Diagnostics & COO | 11.2K | 0.01% | Mar 30, 2026 |
| Amy B. Summy | officer: EVP, Chief Marketing Officer | 7.0K | 0.01% | Aug 6, 2026 |
| Bryan T. Vaughn | officer: EVP and President, Diagnostics | 6.7K | 0.01% | Jul 6, 2026 |
| Dwight Gary Gilliland | director | 6.7K | 0.01% | Aug 1, 2025 |
36 people have not refiled in the last 18 months (1.09M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 17, 2026 | Kerrii B. Andersondirector | Sale | 3,000 | $318.02 | 6,563 |
| Aug 11, 2026 | Adam H. Schechterdirector, officer: President & CEO | Sale | 4,669 | $320.37 | 102,565 |
| Aug 4, 2026 | Amy B. Summyofficer: EVP, Chief Marketing Officer | Sale | 924 | $306.74 | 6,956 |
| Aug 3, 2026 | Peter J. Wilkinsonofficer: SVP, Chief Accounting Officer | Sale · 2 lots | 1,420 | $309.23 | 1,770 |
| Jul 2, 2026 | Bryan T. Vaughnofficer: EVP and President, Diagnostics | Sale | 234 | $286.19 | 6,746 |
| Jul 2, 2026 | Kathryn W. Kyleofficer: EVP, Chief Legal Officer | Sale | 92 | $286.19 | 3,904 |
| Jun 8, 2026 | Kathryn W. Kyleofficer: EVP, Chief Legal Officer | Sale | 762 | $263.89 | 3,813 |
| May 11, 2026 | Adam H. Schechterdirector, officer: President & CEO | Sale | 5,903 | $254.50 | 107,234 |
| Mar 27, 2026 | Jonathan C. Meltzerofficer: EVP, Operations | Sale | 839 | $267.05 | 3,620 |
| Mar 27, 2026 | Peter J. Wilkinsonofficer: SVP, Chief Accounting Officer | Sale | 1,633 | $267.05 | 1,852 |
CongressHouse and Senate disclosures
Not reported.